Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide
Status:
Recruiting
Trial end date:
2026-05-31
Target enrollment:
Participant gender:
Summary
Tuberculosis (TB) treatment is long and complex with the risk of poor treatment adherence and
treatment failure. Several attempts to shorten treatment of drug-susceptible TB have been
unsuccessful. However, recent data support a shortened regimen for mild and moderate
pulmonary TB and simultaneous optimization of rifampicin (RIF) and pyrazinamide (PZA).
This phase II clinical study aim to investigate a strategy to shorten TB treatment by
exploring safety and drug exposure of a high-dose sterilizing TB regimen.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Linkoeping
Collaborators:
Kalmar County Hospital Karolinska University Hospital Linkoeping University Ryhov County Hospital